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In the winter of 2015, the first dengue vaccine (Dengvaxia) 
was approved for clinical use. Dengue virus is the most 
prevalent mosquito-transmitted viral pathogen in humans 
(Qin and Shi, 2014). Even though the approved Dengvaxia 
has its weaknesses (e.g., low protection against serotype-2 
virus), it has been recently licensed to Mexico, Philippines, 
and Brazil. While the world is celebrating the first dengue 
vaccine, another mosquito-borne virus, Zika virus (ZIKV), 
emerged to cause global threat, causing thousands of infants 
with brain defects and adults with neurological diseases 
(Fauci and Mores, 2016). In December 2015, the World 
Health Organization (WHO) added ZIKV to the second tier 
of three diseases ranked as serious, and issued travel warn-
ings to ZIKV epidemic areas (with more than twenty-three 
countries). The ongoing pandemic is explosive. More than 
four million ZIKV infections are expected in America by 
the end of 2016. 
HISTORY AND CURRENT STATUS OF ZIKV 
ZIKV was first isolated from a Rhesus monkey in the Zika 
forest in Uganda in 1947. The virus was subsequently iso-
lated from a human in Nigeria in 1954. Until 2007, ZIKV 
activity had been restricted in African continent and a few 
Asian countries; only 14 sporadic human cases had been 
documented. Since 2007, ZIKV has expanded outside of 
Asia and Africa, causing an outbreak on Yap island in Mi-
cronesia with 49 confirmed and 59 probable cases of ZIKV 
infections (Duffy et al., 2009). Subsequently, a major ZIKV 
epidemic occurred in French Polynesia in 2013, followed by 
rapid spread to countries in Oceania. Meanwhile, imported 
cases were also reported in Norway, Germany, Australia, 
France, Canada, Japan, and Italy (Cao-Lormeau and Musso, 
2014). 
In 2015, the largest ZIKV outbreak took place in Brazil, 
resulting in an estimated 440,000–1,300,000 cases (Bogoch 
et al., 2016). Subsequently, ZIKV began to rapidly spread 
northwards across South and Central America, reaching 
Mexico by late November 2015. According to WHO and 
Pan American Health Organization (PAHO), between No-
vember 2015 and January 2016, local transmission of the 
virus was detected in 14 new countries and territories in 
America. The first case of ZIKV in the United States was 
reported in January 2016 in a traveler who recently returned 
from Latin America to Texas (McCarthy, 2016).  
BIOLOGY AND TRANSMISSION OF ZIKV 
ZIKV is a single-stranded, positive-sense, RNA virus. The 
virus belongs to the Spondweni serocomplex within the 
genus Flavivirus, family Flaviviridae. Other mosqui-
to-borne flaviviruses of public health importance include 
dengue, West Nile, Japanese encephalitis, and yellow fever 
viruses. Currently, only 18 full-length genome sequences 
were deposited in the GenBank. Phylogenetic analyses have 
classified the ZIKV strains into the African and Asian line-
ages (Haddow et al., 2012). The current epidemic ZIKV 
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strains in the Americas belong to the Asian lineages (Enfissi 
et al., 2016).  
The genome of ZIKV, approximately 11,000 nucleotides 
in length, contains a single open reading frame (ORF) 
flanked by 5’ and 3’noncoding regions (NCR). The ORF 
encodes a polyprotein with three structural proteins (capsid, 
premembrane or membrane, and envelope) and seven 
non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, 
NS4b, and NS5). The structural proteins form virion, and 
are responsible for virus attachment to cells, membrane fu-
sion, and virion assembly. The nonstructural proteins are 
required for viral replication and evasion of host immunity, 
as demonstrated in other flaviviruses.  
ZIKV is transmitted to humans mainly by Aedes mos-
quito species, the same vector for dengue and yellow fever 
viruses. Multiple Aedes species, including Aedes albopictus, 
aegypti, and polynesiensis, have been evidenced to carry 
and transmit ZIKV efficiently. Other potential transmission 
routes of ZIKV in humans include perinatal, sexual, verti-
cal, and transfusion transmission. Such non-mosquito 
transmission routes have also been confirmed for other 
mosquito-borne viruses. Since eighty percent of ZIKV in-
fections (see below) are asymptomatic, the transmission 
route of blood transfusion raises the need for testing ZIKV 
contamination in blood bank. Without vaccine and thera-
peutics, mosquito control and avoiding mosquito bites are 
the most effective means to prevent ZIKV infection.   
CLINICAL MANIFESTATIONS 
Like many other arboviral infections, a substantial 
proportion of ZIKV infections are subclinical and 
asymptomatic. The disease caused by ZIKV infection is 
usually mild and requires no special medical treatment or 
hostiptalization. The most common clinical manifestations 
include fever, myalgia, rash as well as eye pain and 
prostration. Infected individuals usually recover in a week. 
Guillain-Barré syndrome and other neurologic conditions 
(including meningitis, meningoencephalitis, and myelitis) 
are also observed in recent outbreaks in the Pacific area. 
The clinical manifestations are very similar to dengue and 
many other arboviral infections.  
Prior to the recent epidemics, ZIKV infection was not 
reported to cause severe diseases (such as hemorrhagic fe-
ver) or death. However, the ongoing epidemic of ZIKV in-
fection in Brazil is correlated to a 20-fold increase in inci-
dence of microcephaly, a rare neurological condition at 
birth in which the newborn’s head is much smaller than 
normal. Children with microcephaly usually have develop-
mental issues and need life-time support. As of January 
2016, Brazil's Health Ministry has reported a total of 3,530 
case of microcephaly, including 46 deaths. Importantly, 
ZIKV was isolated from the amniotic fluid of the mothers; 
in addition, ZIKV was detected from a Brazilian infant with 
microcephaly who died shortly after birth (Vogel, 2016). 
Macular neuroretinal atrophy was also seen in infants with 
microcephaly (Ventura et al., 2016). Despite lack of direct 
evidence, Brazilian authorities have claimed great risk of 
microcephaly appeared to be associated with ZIKV infec-
tion during the first trimester of pregnancy. The public 
health officers even suggest postpone pregnancy to mini-
mize the risk of babies with microcephaly. On 17 January 
2016, WHO issued an epidemiological alert about the asso-
ciation of ZIKV infection with congenital malformations 
and neurological syndromes (PAHO, 2016).  
CHALLENGE AND PROSPECT  
ZIKV is expanding rapidly throughout the world with 
unique characters that have never been seen in other fla-
viviruses. Although ZIKV has been identified for nearly 70 
years, there is a large knowledge gap about this virus and its 
diseases. First, it is critical to study the ecologic, entomo-
logic, viral, and host determinants that account for its rapid 
transmission and disease association. Viral genome analysis 
combined with reverse genetic studies will help identify 
potential viral determinants (Zhao et al., 2014). Second, 
flavivirus infection has never before been linked to birth 
defect. Clinical investigation, animal models (that can reca-
pitulate human diseases), and laboratory studies are needed 
to explain this unexpected result. At the current time, mos-
quito control remains to be the most effective way to reduce 
ZIKV infection. Vaccine development is urgently needed to 
stop ZIKV infection. Based on the success of vaccines 
against other flaviviruses (Japanese encephalitis, yellow 
fever, tick-borne encephalitis, and dengue), both live atten-
uated and inactivated ZIKV vaccines can be envisioned in 
the future. The timeline for ZIKV vaccines could be years 
away due to the development process. 
Currently, no case of ZIKV infection has been reported 
in mainland China. However, in parallel to the recent expe-
rience with dengue and Chikungunya, we expect that im-
ported and autochthonous cases of ZIKV infections will 
appear in China in the coming years. China annually has 
84,332 travelers from ZIKV epidemic areas (Bogoch et al., 
2016); the introductions of similar mosquito-borne viruses 
by tourists have already been documented for dengue and 
chikungunya. Due to the wide distribution of Aedes mos-
quitoes in China, autochthonous outbreak will be inevitable 
following the imported cases. To reduce imported ZIKV 
infections, we recommend that travels to ZIKV-epidemic 
regions be minimized, especially for women who are preg-
nant or about to become pregnant. When visiting ZIKV- 
epidemic regions, travelers should take appropriate meas-
urements to minimize mosquito bites. Since majority of 
ZIKV-infected individuals are asymptomatic, molecular 
diagnostics is needed to monitor the prevalence of ZIKV 
infection in population. Rapid diagnostic assays (including 
detection of virus and serology method) are critically need-
ed to monitor the spread of ZIKV and patient care. The 
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government, public health system, hospitals, and science 
community need work together to prepare, prevent, and 
control this emerging flaviviral pathogen.  
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